Status:
COMPLETED
Study Evaluating Bazedoxifene/Conjugated Estrogen Combinations in Symptoms Associated With Menopause
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Vasomotor Symptoms Associated With Menopause
Eligibility:
FEMALE
40-64 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective in the treatment of moderate to severe vasomotor symptoms associated with menopause.
Eligibility Criteria
Inclusion
- Generally healthy, postmenopausal women, aged 40 to 64, with last natural menstrual period completed at lease 6 months ago
- Intact uterus
- Seeking treatment for hot flushes and experiencing 7 moderate to severe hot flushes per day or 50 per week
Exclusion
- History of active presence of thrombophlebitis, thrombosis, thromboembolic disorders
- History of active presence of stroke, TIA, heart attack or ischemic heart disease
- History of melanoma, breast or any gynecologic cancer at any time; history of any other cancer within the past 5 years
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2007
Estimated Enrollment :
325 Patients enrolled
Trial Details
Trial ID
NCT00234819
Start Date
October 1 2005
End Date
February 1 2007
Last Update
December 28 2007
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
Phoenix, Arizona, United States, 85105
2
Fort Myers, Florida, United States, 33916
3
North Port Richey, Florida, United States, 34652
4
Scarborough, Maine, United States, 04074